PI16

Across TCGA pan-cancer cohorts, PI16 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PI16’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PI16 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PI16 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where PI16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PI16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−1.666	<.001	11	view →
LUAD	Female	III,IV	−1.560	<.001	9	view →
LSCC	Male	All	−1.466	<.001	9	view →
COAD	All	All	−1.379	<.001	6	view →
PDAC	All	II,III,IV	−0.534	.004	4	view →
CCRCC	Male	III,IV	−0.449	.004	4	view →
OV	All	All	−1.915	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PI16–HNSC

Open the HNSC breakdown →